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Topical application of dibenzo[a,l ]pyrene (DB[a,l ]P) to the dorsal skin of SENCAR mice induces codon 61 (CAAGln
to CTALeu) mutations in the Harvey (H)-ras gene within 12 h after treatment. Between days 1 and 3, the frequency of
these mutations increases rapidly, suggesting that skin cells carrying the codon 61 mutations proliferate in this
period. We have investigated DB[a,l ]P-treated mouse skin (12 h–7 d) for further evidence of H-ras expression and
epidermal cell proliferation. Two waves of cell proliferation were observed: the ﬁrst wave (1–2 d) correlated with the
clonal proliferation of codon 61-mutated cells, and the second wave (3–7 d) correlated with DB[a,l ]P-induced
hyperplasia. DB[a,l ]P-induced early preneoplastic cell proliferation correlated with H-ras and specific G1 cyclin
expression. Total H-ras protein and cyclin D1 were found to increase during DB[a,l ]P-induced hyperplasia, but the
levels of guanosine triphosphate-bound (active) H-ras protein and cyclin E were increased during the putative
clonal proliferation of codon 61-mutated cells. These results suggest that DB[a,l ]P-induced oncogenically mutated
cells proliferate in early preneoplastic skin. As this proliferation occurs in the absence of any promoting treatment,
we propose that this phenomenon is a tumor initiation event.
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Mutations in three ras genes, H-, K-, and N-ras, are fre-
quently associated with cancer (Bos, 1989; Barbacid, 1990;
van der Schroeff et al, 1990). K- and N-ras gene mutations at
codons 12 and 13 are the most common (Bos, 1989; Barb-
acid, 1990), but codon 61 mutations in all three ras genes
have also been reported (Grendys et al, 1997; Shiraishi et al,
1998; Esapa et al, 1999; Semczuk et al, 2001). Environmental
carcinogens may have a major role in inducing oncogenic ras
mutations (Vahakangas et al, 2001; Li et al, 2002).
The SENCAR mouse skin carcinogenesis model has
been extensively used to examine the induction of H-ras
mutations by environmental carcinogens such as polycyclic
aromatic hydrocarbons (PAH) (Chakravarti et al, 1995). Two
lines of evidence suggest that mutated H-ras is involved
in tumor initiation in mouse skin. First, PAH such as di-
benzo[a,l ]pyrene (DB[a,l ]P) and 7,12-dimethylbenz[a]anthra-
cene (DMBA) induce oncogenic H-ras mutations very early
in tumorigenesis (Chakravarti et al, 1998, 2000 and un-
published results). Second, cells carrying the mutated
H-ras gene can form benign tumors (Roop et al, 1986).
The mutated H-ras gene is, however, found at all stages of
tumorigenesis (Kemp et al, 1994) and is also involved in
tumor progression (Rodriguez-Puebla et al, 1999a; Nagase
et al, 2003).
Evidence suggests that non-cycling cells play a major
role in tumor initiation. For example, DMBA induces 3-fold
(males) and 13-fold (females) more skin tumors when the
dorsal skin of mice is treated in the resting phase than in
the proliferative phase (Andreasen, 1953). In another study,
mouse skin was treated with 5-fluorouracil (5-FU) either 1 d
before or 1 d after treatment with DMBA (Morris et al, 1997).
These results showed that 5-FU only marginally reduced the
number of benign tumors and did not affect the yield of
carcinomas. As pre-treatment with 5-FU stopped DNA syn-
thesis for 2 d and specifically killed the cycling cells, the
marginal reduction in the yield of papillomas suggests that
quiescent cells contribute more to tumor initiation than cy-
cling cells (Morris et al, 1997). DNA-damaged quiescent
cells would be expected to induce mutations by erroneous
repair. Our studies in mouse skin suggest that erroneous
DNA repair of DB[a,l ]P-induced apurinic sites generates
preneoplastic H-ras mutations (Chakravarti et al, 1998,
2000). Thus, erroneous repair of damaged DNA in quiescent
cells is a major mechanism of tumor initiation.
Relatively little is known about the fate of the cells that
have acquired oncogenic ras mutations. Although PAH
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induce DNA adducts in the entire epidermis, most of the
adducted cells are lost during epidermal renewal, and pre-
sumably do not contribute to tumor formation (Morris et al,
1986). Tumors are thought to arise from the remaining ‘‘in-
itiated’’ cells that escape epidermal turnover and subsist as
slowly cycling cells in the basal epidermis, as well as in the
hair follicles of skin (Bickenbach et al, 1986; Morris et al,
1986, 2000). The slow-cycling cells retain a stem cell-like
high proliferative potential (Morris and Potten, 1994; Morris,
2000). The slow-cycling cells of the early preneoplastic pe-
riod, however, have not been shown to carry oncogenic ras
gene mutations.
DB[a,l ]P-treated SENCAR mouse skin (12 h–1 d) showed
a high frequency of mutations (oncogenic codon 61 and
other mutations) in the H-ras gene (Chakravarti et al, 1998,
2000). In this period, the mutations were found to be in the
form of mismatched heteroduplexes as would be expected
from erroneous repair. Consistent with this idea, recent
studies indicate that DB[a,l ]P treatment induces base ex-
cision repair genes during the mutagenic period (4–24 h)
(Chakravarti et al, 2004). Following the initial period of er-
roneous repair-induced mutagenesis, there was a transient
(1–3 d) increase in the frequency of oncogenic codon 61
mutations. In this period, the mutations did not appear as
mismatched heteroduplexes, but were present as ‘‘fixed’’
mutations, as would be expected from a round of replication
that would synthesize complementary daughter strands and
separate the DNA into two molecules. Finally, between 4
and 7 d, the skin rapidly lost a majority of the H-ras mu-
tations. Based on these results, we hypothesize that in
DB[a,l ]P-treated skin, cells that acquire the oncogenic H-ras
codon 61 mutations transiently proliferate, but subsequent-
ly, only a small subpopulation of these cells persists in skin
to form tumors, whereas a majority of the mutated cells are
lost. We speculate that not all of the codon 61-mutated cells
were stem cells. Indeed, the rapid regression of mutations
(days 4–7) suggests that the partially differentiated mature
or ‘‘transit’’ cells, which represent the majority of cells in the
epidermis, also acquire the codon 61 mutation, divide once,
and terminally differentiate to lose their nuclei and are shed
from skin (Dover, 1994).
We describe this phenomenon of putative transient pro-
liferation and regression of codon 61-mutated cells as tran-
sient clonoplasia (Chakravarti et al, 2000). As these events
occur without any promoting treatments (e.g. with phorbol
ester) to the skin, we propose that these events are part of
the process of tumor initiation. In this paper, we provide
further evidence for unpromoted early-preneoplastic prolif-
eration. In addition, we report an apparent correlation be-
tween proliferation, H-ras expression, and signaling.
Results
Expression of H-ras protein in DB[a,l ]P-treated mouse
skin Our previous studies suggested that DB[a,l ]P treat-
ment of SENCAR mouse skin results in rapid induction
(within 12 h) of oncogenic H-ras codon 61 (CAAGln to
CTALeu) mutations (Chakravarti et al, 1998, 2000). Following
mutagenesis, the frequency of the codon 61 mutations in
skin clonally increased for a brief period (days 1–4) and then
regressed rapidly (days 4–7). These results suggested that
cells that acquire the codon 61 mutation clonally proliferate
for a brief period (days 1–4) and then are eliminated (days 4–
7) from the skin. The rapid regression of codon 61 mutations
coincided with DB[a,l ]P-induced hyperplasia that approxi-
mately doubles the skin layer (Casale et al, 2000).
We studied the expression of H-ras protein in DB[a,l ]P-
treated mouse skin to examine whether these preneoplastic
events are correlated with H-ras mutation. Immunoprecip-
itation (IP) western blot analysis (Fig 1A and B) showed that
DB[a,l ]P treatment induced increased expression of the
Figure 1
Levels of total and guanosine tripho-
sphate (GTP)-bound H-ras protein in
dibenzo[a,l]pyrene (DB[a,l ]P)-treated
SENCAR mouse skin. (A, B) Changes
in the levels of total H-ras protein in the
early preneoplastic period (12 h–7 d). (C,
D) Changes in the levels of GTP-bound
H-ras protein. The error bars in the bar
charts (B, D) show the variability of re-
sults obtained from three independent
immunoprecipitation western experiments
with skins from two different mice/time
point. (E) Levels of H-ras remained un-
changed by the single treatment with
acetone. The levels of b-actin in pre-
immunoprecipitated extracts are shown
as loading control.
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H-ras gene that became evident at day 1, peaked between
days 2 and 5, became highest at day 3 (  3-fold over un-
treated skin), and then declined to near-untreated levels by
day 7. The levels of guanosine triphosphate (GTP)-bound H-
ras also increased, essentially following the expression pat-
terns of total H-ras, except that its level showed a plateau
between days 2 and 4 (Fig 1C and D). For total H-ras, the
slope of time (0.5724; po0.0001) and time squared
(0.0821; po0.0001) were significantly different from zero,
indicating that total H-ras tends to follow a quadratic curve
with expected peak activation at  3.5 d. For active H-ras,
the slope of time (0.4642; po0.0001) and time squared
(0.0687; po0.0001) were significantly different from zero,
with expected peak activation at  3.4 d.
The early plateau of GTP-bound H-ras suggests that skin
cells contained a higher fraction of active H-ras at day 2
than at day 3, when the highest level of H-ras is observed.
These results are consistent with the idea that cells carrying
H-ras codon 61 mutations briefly proliferate (days 1–2),
express the mutated H-ras gene, forming constitutively
GTP-bound H-ras protein (Krengel et al, 1990; Scheffzek
et al, 1997; Ahmadian et al, 1999), and then are eliminated,
as suggested by the mutational data (12, 13). These results
also raise the possibility that mutated H-ras might drive the
proliferation of these cells.
The IP western experiments show relative changes in the
levels of H-ras protein, but did not provide the knowledge of
the actual levels of total and GTP-bound H-ras proteins. To
quantify the levels of GTP-bound and total H-ras protein, we
conducted quantitative ELISA experiments. A typical stand-
ard curve for these experiments is shown in Fig 2. The results
indicate that the fraction of GTP-bound H-ras protein in
DB[a,l ]P-treated mouse skin was approximately 3%–6% of
the total H-ras protein. A change in the total H-ras protein in
the early preneoplastic period was clearly observable. For
total H-ras, the slope of time (0.3255; po0.0001) and time
squared (0.0348; po0.0001) were also significantly differ-
ent from zero, again indicating that total H-ras tended to
follow a quadratic curve, with expected peak activation at
 4.7 d. For active H-ras, the coefficient for time (0.1218;
p¼ 0.02) was significant; however, the slope for time squared
(0.0132; p¼ 0.07) was not significantly different from zero.
Two periods of increased H-ras expression were dis-
cernible (1 and 3–6 d), corresponding to the two putative
periods of preneoplastic cell proliferation, namely, clonal
proliferation of codon 61-mutated cells and DB[a,l ]P-
induced hyperplasia (Casale et al, 1997, 2000) (Fig 2B).
The hyperplastic response is known to increase the number
of epidermal cells (from the single-layer epidermis in un-
treated skin to a bilayer at day 7 and multilayer at day 10
after treatment with 200 nmol DB[a,l ]P) (Casale et al, 2000).
The peak level of H-ras protein by the ELISA experiments
was  2.5-fold over control (see Table S1).
Both IP western experiments (Fig 1) and the ELISA ex-
periments (Fig 2) showed increased H-ras levels. The ELISA
experiments, however, did not trace an identical profile as in
the IP western experiments. Presumably, these differences
are because of the enrichment of H-ras in the IP western
experiments. The ELISA analysis was not sufficiently sen-
sitive to track DB[a,l ]P-induced changes relative to control
levels of GTP-bound H-ras protein (see Table S1).
Epidermal cell kinetics in DB[a,l ]P-treated mouse skin
The results of fluorescence-activated cell sorter (FACS)
analysis of nuclear DNA content in propidium iodide-stained
epidermal cells isolated from DB[a,l ]P-treated dorsal skin
are shown in Fig 3A. Two waves of DNA synthesis are ob-
served: the first correlated with the putative clonal prolifer-
ation of the codon 61-mutated cells (1–2 d) and the second
correlated with epidermal hyperplasia (3–6 d). Epidermal
cells isolated from untreated control mice, as well as ep-
idermal cells isolated from the belly skin of the treated mice,
did not show these changes in cell kinetics (data not
shown).
Figure2
Quantification of total and guanosine triphosphate (GTP)-bound H-
ras protein levels in dibenzo[a,l]pyrene (DB[a,l ]P)-treated mouse
skin. (A) Representative standard curve constructed with pure H-ras
protein. (B). Comparative levels of total and GTP-bound H-ras protein in
DB[a,l ]P-treated mouse skin. Results of two ELISA experiments from
two different mice/time point are shown.
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Epidermal cell kinetics in DB[a,l ]P-treated skin was also
examined by following the levels of proliferating cell nuclear
antigen (PCNA) (Fig 3B and C). DB[a,l ]P treatment resulted
in increased PCNA levels at two time periods, between days
1 and 2 ( 1.6-fold) and, again, between days 3 and 7
( 4-fold). The slope of time (0.6273; po0.0001) and time
squared (0.0663; po0.0001) were significantly different
from zero, indicating that like H-ras, PCNA also tends to
follow a quadratic curve with expected peak activation at
 4.7 d. Therefore, these results are consistent with the
idea that epidermal cells in DB[a,l ]P-treated skin undergo
two distinct waves of replicative DNA synthesis that corre-
spond to the unpromoted clonal proliferation of codon 61-
mutated cells and the DB[a,l ]P-induced hyperplasia.
Induction of G1 cyclins Previous studies with the two-
stage carcinogenesis model suggest that cylin D1 is not
overexpressed in normal or hyperproliferative skin, but
overexpressed in premalignant lesions and carcinomas
(Bianchi et al, 1993; Robles and Conti, 1995). These and
other studies suggested that oncogenic H-ras and cyclin D1
overexpression play a major role in tumor formation (Robles
et al, 1998; Rodriguez-Puebla et al, 1998, 1999b; Miliani De
Marval et al, 2004). It was, however, reported that v-H-ras
induces cyclins D1, D2, and E in primary mouse keratin-
ocytes (Robles et al, 1998). Changes in the levels of G1
cyclins (cyclins D1, D2, and E) in DB[a,l ]P-treated mouse
skin are shown in Fig 4. Cyclin D1 was found to increase
during DB[a,l ]P-induced hyperplasia (maximal induction at
day 5), but not during the putative unpromoted proliferation
of codon 61-mutated cells (Fig 4A and B). The cyclin D2
protein level did not change significantly (Fig 4C and D) and
cyclin D3 protein could not be detected (data not shown).
An earlier study also reported poor cyclin D3 expression in
mouse skin (Robles et al, 1998). The levels of cyclin E pro-
tein, on the other hand, were found to increase (days 1–3)
during the putative clonal proliferation of codon 61-mutated
cells (Fig 4E and F ).
Discussion
Our previous studies (Chakravarti et al, 1998, 2000) and the
present data are consistent with the idea that epidermal
cells carrying H-ras codon 61 mutations briefly undergo
clonal proliferation. An increase in the levels of GTP-bound
H-ras protein was observed during this period (1–4 d, Fig 1).
These profiles resemble our previous observations on the
induction of codon 61 mutations in DB[a,l ]P-treated mouse
skin (Chakravarti et al, 1998, 2000). But changes in the lev-
els of GTP-bound H-ras protein were under the limit of
sensitivity of quantification by the ELISA procedure (Fig 2).
To our knowledge, these are the first studies about the early
preneoplastic profiles of H-ras gene expression and epi-
dermal cell proliferation in PAH-treated skin. A previous
study indicated that DMBA-treated Long–Evans rats pro-
duce preleukemic cells carrying the codon 61-mutated N-
ras gene within 48 h after treatment (Osaka et al, 1996). It
was later found that N-ras mRNA is overexpressed at this
time, but whether the increased expression was because
of the codon 61-mutated N-ras gene was not examined
(Gyongyi et al, 2002).
We observed a small but significant increase in the S-
phase population of epidermal keratinocytes and a corre-
sponding increase in PCNA levels during the putative clonal
proliferation of H-ras codon 61-mutated cells (Fig 3). A
second wave of cell proliferation occurred during DB[a,l ]P-
induced epidermal hyperplasia. Further evidence for two
waves of cell proliferation was obtained from the profiles of
G1 cyclins. Cyclin E levels were increased during the pu-
tative clonal proliferation of H-ras codon 61-mutated cells
whereas cyclin D1 levels were increased during hyperplasia.
Ras can transduce a variety of proliferative, apoptotic,
senescent, and differentiation signals (Crespo and Leon,
2000; Malumbres and Barbacid, 2003). In particular, growth
signaling by oncogenically mutated ras is important for
tumor formation. For example, a number of transcription
factors, including Ets, c-jun, c-myc, NF-kB, and C/EBPb,
Figure 3
Epidermal cell proliferation in di-
benzo[a,l ]pyrene (DB[a,l ]P)-treated
mouse skin. (A) Cell kinetics (fluores-
cence-activated cell sorter analysis of
propidium iodide-stained nuclei) of kera-
tinocytes isolated from DB[a,l ]P-treated
skin. Each time point shows the cell ki-
netic analysis of pooled keratinocytes
from four to five SENCAR mice, deter-
mined in triplicate. (B, C) Induction of
proliferating cell nuclear antigen (PCNA)
levels (as a marker of DNA replication) in
DB[a,l ]P-treated skin. Immunoprecipita-
tion western experiments indicate that
the levels of PCNA increased in two
waves, corresponding to the cell kinet-
ics. The correlations between the two
putative proliferation events with prolifer-
ation of codon 61-mutated cells and
DB[a,l ]P-induced hyperplasia are shown.
The error bars in the bar chart show
the variability of results obtained from
three independent experiments obtained
from two to three mice/time point. (D)
Expression of PCNA in acetone-treated
mouse skin.
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have been reported to have roles in oncogenic ras-medi-
ated cellular transformation (Sklar et al, 1991; Langer et al,
1992; Johnson et al, 1996; Finco et al, 1997; Zhu et al,
2002). Earlier studies suggest that oncogenic H-ras utilizes
cyclin D1 as a primary downstream signal for G1–S tran-
sition, but cyclins D2 and E may also have significant roles
(Robles et al, 1998).Our results indicate that cyclin E levels
are increased during the putative clonal proliferation of co-
don 61-mutated cells, and cyclin D1 levels are increased
during the hyperplastic period. These results are correlative,
and do not prove that the putative unpromoted proliferation
of codon 61-mutated cells occurs through a cyclin E-
mediated mechanism. As DB[a,l ]P-treated skin cells carry
various mutations between days 1 and 2 (Chakravarti et al,
2000), a direct correlation between the increment in the level
of cyclin E and the expression of codon 61-mutated H-ras
protein is not possible from these results. These results
could also be confounded by DB[a,l ]P-induced toxicity and
homeostatic proliferation of skin cells. A role of cyclin E in
oncogenic H-ras signaling, however, has been indicated in
other systems (Ludde et al, 2001; Starkel et al, 2001; Geisen
and Moroy, 2002).
In summary, these results suggest that an unpromoted
clonal proliferation of oncogenically mutated cells in early
preneoplastic mouse skin is an event of tumor initiation.
This clonal proliferation may be correlated with the expres-
sion of activated H-ras and induction of cyclin E protein. We
are conducting further studies to examine whether codon
61 mutations are associated with these events of tumor
initiation.
Materials and Methods
DB[a,l ]P treatment of dorsal skin of SENCAR mice Eighteen
female SENCAR mice (8 wk old; two mice each for nine time
points: 0 h (solvent control), 12 h, 1, 2, 3, 4, 5, 6, and 7 d) were
treated with 200 nmol of DB[a,l ]P in 100 mL acetone on an area of
shaved dorsal skin, as described previously (Chakravarti et al,
1998). At this dose, the tumor yield is five to seven per animal and
significant skin toxicity is observed (Casale et al, 1997, 2000). This
dose was chosen for the current experiments because, at DB[a,l ]P
doses lower than 200 nmol, a diminished frequency of early H-ras
codon 61 mutations is observed (unpublished results). Mice were
sacrificed at indicated times, and treated dorsal skin was harvest-
ed, flash-frozen in liquid N2, and stored at 801C until use. The
medical ethical committee of the University of Nebraska Medical
Center approved all described studies.
Protein extraction from mouse skin All procedures were con-
ducted at 41C. One milligram of skin tissue was finely chopped and
Figure 4
Expression of G1 cyclins in di-
benzo[a,l ]pyrene (DB[a,l ]P)-treated
mouse skin. (A, B) Changes in the lev-
els of cyclin D1 protein. (C, D) Changes
in the levels of cyclin D2 protein. (E, F).
Changes in the levels of cyclin E pro-
tein. The error bars in the bar charts
show the variability of results obtained
from immunoprecipitation western
analyses of three to four independent
determinations with skin harvested
from two to three different mice/time
point. Similar experiments with a single
treatment with 100 mL acetone (vehicle)
did not show changes in the levels of
G1 cyclins (not shown).
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homogenized in a mortar and pestle in 2.5 mL ice-cold RIPA buffer
(50 mM Tris, 5 mM EDTA, 150 mM NaCl, 0.25% sodium-de-
oxycholate, and 1% NP-40, pH 7.5), and centrifuged at 13,000
r.p.m. (15,700 g) for 15 min to collect the supernatant. To extract
protein from larger sections of skin samples, this protocol was
scaled up. Protein concentration was determined by the Comassie
Plus reagent (Pierce Biotechnology, Rockford, Illinois). The extracts
were used for immuoprecipitation western blots and ELISA assays.
IP western blotting The expression of PCNA, G1 cyclins, and H-
ras protein in untreated or DB[a,l ]P-treated SENCAR mouse skin
was examined by this protocol. Unless otherwise stated, all pro-
cedures were conducted at 41C. In these experiments, 0.1–1 mg
aliquots of the extracted protein were diluted with phosphate-buff-
ered saline (PBS) (pH 7.4, Sigma Biochemicals, St Louis, Missouri)
to 100 mL, precleared by incubating for 30 min with 10 mL of Protein
A sepharose (Amersham Biosciences, Piscataway, New Jersey),
and centrifuged at 13,000 r.p.m. for 15 min. The supernatants were
incubated with 5 mL of undiluted primary antibody for 3 h with
shaking. Into these mixtures, 20 mL of protein A sepharose was
added and incubated overnight with shaking. After centrifugation
(13,000 r.p.m. for 15 min), the immunoprecipitated pellets were
harvested and washed six times with PBS, resuspended in 10 mL of
2  SDS-PAGE sample loading buffer (Laemmli, 1970), and boiled
for 5 min at 1001C. Boiled supernatants were harvested by cen-
trifugation (13,000 r.p.m. for 5 min) and electrophoresed in a 12%
SDS-PAGE gel (Laemmli, 1970).
The gels were electroblotted onto PVDF membranes (Millipore
Corporation, Bedford, Massachusetts) at 400 mA for 2 h. The
membranes were blocked overnight with TBST (50 mM Tris, 150
mM NaCl, pH 7.5, supplemented with 0.1% Tween-20) containing
2% BSA (Sigma Biochemicals), and then washed five times with
TBST. The blots were incubated with appropriate dilutions of the
primary antibodies for 1 h at room temperature, washed, and in-
cubated with secondary antibody (HRP-linked IgG) (Santa Cruz
Biotechnology, Santa Cruz, California), and developed with the
ECL kit according to vendor (Amersham Biosciences). Antibodies
against PCNA (sc-56), H-ras (sc-520), and cyclins D1 (sc-246), D2
(sc-452), D3 (sc-6283), and E (sc-481) were obtained from Santa
Cruz Biotechnology. A Raf-1 RBD-agarose conjugate (14–278) was
obtained from Upstate Biotechnology (Charlottsville, Virginia).
Quantitative ELISA of total and GTP-bound H-ras protein An
ELISA technique (Engvall and Perlmann, 1972) was adapted for the
quantification of total or GTP-bound (active) H-ras protein levels in
untreated and DB[a,l ]P-treated SENCAR mouse skin.
Standard curves A purified H-ras protein (Cytoskeleton, Denver,
Colorado) was diluted in bicarbonate buffer (pH 9.0) (Engvall and
Perlmann, 1972) generating standard curves for the measurement
of total (200 fmol–3.2 pmol) or active (0.2 fmol–3.2 pmol) H-ras
proteins.
To generate the standard curves, various amounts of H-ras
protein (diluted to an uniform volume of 100 mL with bicarbonate
buffer) were spotted in the wells of a microtiter plate (Immplate
MaxiSRP, Nalge NUNC, Rochester, New York), and incubated
overnight at 41C. The plate was washed 4  with a PBST wash
buffer (10 mM PBS, pH 7.4, with 0.05% Tween 20), blocked for 1 h
with 150 mL of PBST containing 1% BSA (blocking buffer) at room
temperature, washed again, and incubated with 100 mL of blocking
buffer containing 1:100 dilution of anti-H-ras antibody for 1 h at
room temperature. The plate was washed 4  with PBST as
described above, and blocked with 100 mL of blocking buffer
containing a 1:5000 dilution of the secondary antibody (anti-goat
IgG-Biotin, Sigma Biochemicals) and added to the wells and in-
cubated for 1 h at room temperature. Again, the plate was washed
4  with PBST as above, and incubated for 1 h at room temper-
ature with 100 mL of a 1:100 dilution of avidin–alkaline phosphatase
(Sigma Biochemicals) in blocking buffer. The plate was washed
4  with PBST as above and color developed with 100 mL of
p-nitrophenyl phosphate solution (1 mg per mL) (Sigma Biochem-
icals) for 15 min at room temperature. Reactions were stopped with
100 mL of 1 M NaOH, and the color was measured at 405 nm.
Quantiﬁcation of total and GTP-bound H-ras in untreated or
DB[a,l ]P-treated SENCAR mouse skin Total H-ras protein in un-
treated or DB[a,l ]P-treated mouse skin samples was determined
using 80 mg protein extracts. The procedures were similar to that
for the generation of standard curves, except that a 1:500 dilution
of the anti-H-ras antibody was used. To determine the GTP-bound
ras levels in these samples, 200 mg of protein extracts were used.
The GTP-bound ras in the extract was immunoprecipitated with 10
mL Raf-1 ras-binding domain (RBD)–agarose conjugate for 30 min
at 41C in a rotary shaker. The precipitated protein conjugate was
harvested by centrifugation (13,000 r.p.m. for 15 min at 41C), the
pellet was washed 3  with ice-cold bicarbonate buffer, and then
resuspended in 100 mL of bicarbonate buffer. GTP-bound ras was
released from the conjugate by heating the slurry at 801C for 3 min
and harvested by centrifugation (13,000 r.p.m. for 5 min at room
temperature). The resulting supernatants were analyzed by ELISA
with anti-H-ras antibody, as described above.
Statistical methods A generalized linear model assuming a log link
and Poisson’s distribution allowing for underdispersion was used
to examine differences over time (days). The dispersion parameter
was estimated as the deviance divided by the degrees of freedom
(McCullagh and Nelder, 1989). Separate analyses for total H-ras,
active H-ras, and PCNA were conducted using time and time
squared as covariates (see Table S1). Wald w2 tests were used to
test whether estimated coefficients were significantly different from
zero. A p-value o0.05 was considered to be significant.
Cell kinetic analysis of epidermal keratinocytes from adult
SENCAR mice Epidermal keratinocytes from untreated or
DB[a,l ]P-treated SENCAR mouse skin were isolated as described
before (Morris and Fischer, 1994). In these experiments, a total of
50 mice (8 wk-old; five each for 10 time points: 0 h (solvent control),
12 h, 1, 2, 3, 4, 5, 6, 7, and 9 d) were used. Briefly, dorsal skins from
five mice were floated on 0.25% trypsin (Invitrogen, Carlsbad,
California) and incubated for 2 h at 321C. The loosened epidermis
was scraped off with paddles and suspended in 30 mL DMEM
containing 10% FBS and 0.2 mg per 100 mL gentamycin (Invitro-
gen). Cells were gently stirred for 20 min and passed through a 40
mm filter and centrifuged. The cell pellet was resuspended in 5 mL
of the above culture medium by trituration. This procedure yielded
1–2 million epidermal cells, of which 490% are keratinocytes.
Cells were added dropwise to a vortexing solution of 70%
ethanol for alcohol fixing, centrifuged and washed once with PBS
(Sigma Biochemicals), suspended in 1 mL Telford reagent (Telford
et al, 1991), and incubated for 30 min at 41C for FACS analysis.
Each sample was divided into three parts and analyzed as rep-
licates. The results were compared with epidermal cell prepara-
tions from the belly skins of the treated animals to determine
whether the skin of these mice was in the resting or proliferating
phases.
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